UBS Group
MTCR

UBS Group’s Metacrine, Inc. Common Stock MTCR Stock Holding History

UBS Group’s Portfolio MTCR Stock Details MTCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,781
Closed -$2.15K – 11420
2022
Q4 		$2.15K Sell
4,781
-37,870
-89% -$15.7K ﹤0.01% 9727
2022
Q3 		$21K Buy
42,651
+32,078
+303% +$15.8K ﹤0.01% 7369
2022
Q2 		$5K Sell
10,573
-15,490
-59% -$7.5K ﹤0.01% 8993
2022
Q1 		$16K Buy
26,063
+24,469
+1,535% +$12.8K ﹤0.01% 7787
2021
Q4 		$1K Buy
1,594
+599
+60% +$1.07K ﹤0.01% 10134
2021
Q3 		$3K Sell
995
-504
-34% -$1.57K ﹤0.01% 8892
2021
Q2 		$6K Sell
1,499
-876
-37% -$3.62K ﹤0.01% 8488
2021
Q1 		$15K Buy
2,375
+895
+60% +$7.93K ﹤0.01% 7648
2020
Q4 		$12K Buy
1,480
+965
+187% +$8.85K ﹤0.01% 7374
2020
Q3 		$5K Buy
+515
New +$5.27K ﹤0.01% 7359

Other funds holding MTCR

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

UBS Group's MTCR Position: Q1 2023 in Review

UBS Group sold out of Metacrine, Inc. Common Stock (MTCR) in Q1 2023, closing a stake of 4,781 shares — an estimated $2.15K sold.

UBS Group first reported a position in MTCR in Q3 2020 and held it in 10 quarters. The position peaked at $21K in Q3 2022. 5 funds tracked by Wall St. Rank hold MTCR as of Q1 2023.

  • UBS Group reported no remaining Metacrine, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • UBS Group sold 4,781 Metacrine, Inc. Common Stock shares in Q1 2023, an estimated $2.15K.
  • UBS Group first reported a position in Metacrine, Inc. Common Stock in Q3 2020 and held it in 10 quarters.
  • UBS Group's Metacrine, Inc. Common Stock position peaked at $21K in Q3 2022.
  • 5 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.